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Pharmacokinetics is a ﬁrst, but essential step to improve population-tailored postoperative analgesia, also after Caesarean delivery.
We therefore aimed to quantify the impact of caesarean delivery on the pharmacokinetics of intravenous (iv) paracetamol (2g,
single dose) and iv ketorolac tromethamine (30mg, single dose) in 2 cohorts eachof 8 women at caesarean delivery and to
comparetheseﬁndingswithpostpartumtoquantifyintrapatientchanges.Wedocumentedahigher medianparacetamolclearance
at delivery when compared to 10–15 weeks postpartum (11.7 to 6.4L/h·m2, P<0.01), even after correction for weight-related
changes. Similar conclusions were drawn for ketorolac: median clearance was higher at delivery with a subsequent decrease (2.03
to 1.43L/h·m2, P<0.05) in postpartum (17–23 weeks). These diﬀerences likely reﬂect pregnancy- and caesarean-delivery-related
changes in drug disposition. Moreover, postpartum paracetamol clearance was signiﬁcantly lower when compared to estimates
publishedinhealthyyoungvolunteers(6.4 versus 9.6L/h·m2),whilethiswasnotthecaseforketorolac(1.43 versus 1.48L/h·m2).
This suggests that postpartum is another speciﬁc status in young women that merits focused, compound-speciﬁc pharmacokinetic
evaluation.
1.Introduction
A drug is administered with the intention to obtain a dose-
related therapeutic eﬀect, preferably without side eﬀects.
Clinical pharmacology aims to predict these eﬀects based
on compound, population, and patient-speciﬁc pharma-
cokinetics (PK, concentration time) and pharmacodynamics
(PD, concentration eﬀect). As recently reviewed in this jour-
nal, pregnancy and postpartum warrant a focused approach
due to the physiological changes throughout pregnancy [1].
First, there are obvious changes in body weight and body
surfaceareathatalreadyresultindiﬀerencesinconcentration
time proﬁles when ﬁxed doses are applied. In addition to
these size-related changes, protein-binding capacity (e.g.,
decrease albumin, pH shifts) may aﬀect drug plasma protein
binding [1–4]. Renal clearance is enhanced during preg-
nancy (i.e., higher glomerular ﬁltration rate, higher active
renal tubular transport). Finally, metabolic activity (e.g.,
oxygen consumption, cardiac output) is also increased often
resulting in increased metabolic drug clearance (phase I and
phase II oxidative metabolism), although alterations are in
part enzyme-speciﬁc. Rarely, enzyme speciﬁc activity (e.g.,
CYP1A2 and CYP2C19) is decreased during pregnancy [1–
4]. Observations on the postpartum involution of these
changes back to prepregnant values are very limited [1–4].
The options for post-caesarean pharmacological pain
management are extensive and in part driven by avail-
ability, preferences, experience, and costs. Most strate-
gies for post-caesarean analgesia rely on opioids, supple-
mented with nerve blocks, adjunctive techniques, and anti-
inﬂammatory analgesics, including intravenous (iv) parac-
etamol (acetaminophen) or iv ketorolac tromethamine [5].
Despitethefactthatthesecompoundsarecommonlyadmin-
istered as part of multimodal analgesia, PK observations at
delivery and in postpartum are almost completely absent.
We aimed to describe iv paracetamol and iv ketorolac PK2 Journal of Biomedicine and Biotechnology
in women immediately following caesarean delivery and
compared these ﬁndings with postpartum, using a paired
study design to quantify intrapatient changes.
2. Methods
2.1. Ethics and Recruitment. Following approval of the study
protocols by the Ethics Committee of the University Hospi-
tals Leuven (EudraCT 2010, 020164-37 and 2011, 000367-
27 resp.), women scheduled for (semi) elective caesarean
delivery were recruited after providing written, informed
consentineithertheivparacetamol(EudraCT2010,020164-
37), or—more recently—the iv ketorolac (EudraCT 2011,
000367-27) pharmacokinetic study.
For both studies, 8 of the women included at delivery
were invited to return for a second pharmacokinetic study
with the same dose of the same compound 10–15 weeks
(for iv paracetamol) or 17–23 weeks (for iv ketorolac) after
delivery (“postpartum”) to quantifyintraindividual pharma-
cokinetic diﬀerences between “at delivery”a n d“ postpartum”
in a paired approach (intraindividual variability).
2.2. Clinical Setting. Anaesthesia for caesarean delivery in
our institution is provided based on combined spinal-
epidural (CSE) anaesthesia with hyperbaric bupivacaine
7.5mg and sufentanil 2.5µg. For the postoperative anal-
gesia following caesarean delivery, a multimodal analgesic
approach is applied and includes the use of iv paracetamol
and iv ketorolac [6].
Shortly after delivery of the newborn, paracetamol 2g
(Perfusalgan, Bristol Myers Squibb, Braine-l’Alleud, Belgium
or Paracetamol Fresenius, Fresenius Kabi, Schelle, Belgium)
is given intravenously over 15 minutes as a loading dose,
followed by 1g of iv paracetamol every 6h for the ﬁrst
24h. Immediately following closure of the skin, bilateral
transversus abdominis plane (TAP) blocks are provided with
0.375% ropivacaine 20mL per side, and iv bolus of ketorolac
(30mg ketorolac tromethamine, equal to 20.345mg of
ketorolac, Taradyl, Roche, Anderlecht, Belgium) is given
e v e r y8 hf o r2 4 h[ 6]. After this ﬁrst 24h time interval,
treatment is continued by oral paracetamol and ibuprofen.
2.3. Clinical Characteristics, Sample Collection, and Analy-
sis. Clinical characteristics [weight and body surface area,
(BSA)] were collected shortly before caesarean delivery or
immediatelybeforethepostpartumPKstudywasperformed.
In postpartum women, breastfeeding was registered. The
duration of administration of iv paracetamol (2g, loading
dose) was recorded, but was aimed to be 15–20 minutes.
Blood samples from a dedicated peripheral iv catheter were
collected at 1, 2, 4, and 6h after loading dose administration.
Plasma samples were centrifuged and stored at −20◦C until
high-performance liquid chromatography (HPLC) analysis
was performed [7]. Similarly, blood samples from a dedi-
cated peripheral iv catheter were collected at 1, 2, 4, 6, and
8h after the ﬁrst ketorolac bolus administration. Racemic
ketorolac was quantiﬁed by HPLC with UV detection [8].
The methodological approach applied (dose, sampling
times, storage, and analysis) following caesareandelivery was
repeated10–15weekspostpartumforwomenincludedinthe
iv paracetamol study, and 17–23 weeks for the iv ketorolac
cohort.
2.4. Pharmacokinetics. A noncompartmental linear dispo-
sition model was used for the analysis of paracetamol
and ketorolac time-concentration proﬁles. The peak and
trough plasma concentrations (Cmax and Ctrough)w e r e
obtained directly from the individual experimental data.
The terminal elimination rate constant (ke) was determined
by log-linear regression analyses of the ﬁnal data points
(at least 3) and calculation of the corresponding slope
(−ke/2.303). The apparent elimination half-life of the log-
linear phase (t1/2) was calculated as 0.693/ke. The area under
the plasma concentration-time proﬁle (AUC) from 0 to 6
hours(AUC0–6)wascalculatedbyusingthelineartrapezoidal
method. The AUC from 6 hours to inﬁnity (AUC6–∞)w a s
determined by dividing the ﬁnal plasma concentration by ke,
and the AUC from 0 hours to inﬁnity (AUC0–∞) was the sum
of AUC0–6 and AUC6–∞. The total plasma clearance (CL) was
determined by dose/AUC0–∞ and the volume of distribution
(Vd)b yC L / ke.
For the ketorolac samples, a similar approach was
applied, but the area under the plasma concentration-time
proﬁle(AUC)from0to8hours(AUC0−8)andtheAUCfrom
8h to inﬁnity (AUC8–∞) were determined. The diﬀerences in
time interval relate to the clinical dosing regimen currently
applied.
2.5. Statistics. Clinical characteristics and individual phar-
macokinetic estimates were reported by median and range.
Results collected at delivery and in postpartum were com-
pared using paired statistics (Wilcoxon, MedCalc, Mariak-
erke, Belgium).
3. Results
The clinical characteristics and individual pharmacokinetic
estimates for the iv paracetamol study are provided in
Table 1. For the iv ketorolac study, the same dataset is
provided in Table 2. Respectively, 6/8 and 3/8 women were
breastfeeding at the time of the postpartum PK study.
For both compounds, there is a signiﬁcant decrease (at
least, P<0.05) in median clearance (22.19 to 11.31L/h and
11.7 to 6.4L/h·m2 for iv paracetamol and 3.80 to 2.53L/h
and 2.03 to 1.43L/h·m2 for iv ketorolac) when observations
in postpartum were compared with observations collected at
delivery, even after correction for BSA-related changes.
Figure 1 illustrates the intraindividual changes in parac-
etamol clearance (L/h·m2) (80% increase at delivery,
decrease in 8/8 cases postpartum). Figure 2 illustrates the
intraindividual changes in ketorolac clearance (L/h·m2)
(40% increase at delivery, decrease in 7/8 cases postpar-
tum). Both ﬁgures provide paired individual estimates with
intraindividual trend lines, mean, and standard deviation.Journal of Biomedicine and Biotechnology 3
Table 1: Clinical characteristics and pharmacokinetic estimates for intravenous paracetamol (single dose, 2g) in 8 women as collected at
delivery and in postpartum (10–15 weeks after delivery). Data provided by median and range.
At delivery Postpartum P value
Body weight (kg) 78.5 (61–92.2) 69 (52.2–88) P = 0.0078
Body surface area, BSA (m2) 1.96 (1.65–2.06) 1.83 (1.51–2.01) P = 0.0078
Clearance (L/h) 22.19 (13.08–27.32) 11.31 (8.06–15.72) P = 0.0078
Clearance (L/h·kg) 0.29 (0.2–0.32) 0.17 (0.15–0.2) P = 0.0078
Clearance/BSA (L/h·m2) 11.7 (7.7–13.3) 6.4 (5.3–7.8) P = 0.0078
Distribution volume (L) 61.7 (43.5–75) 35.7 (29.5–59.3) P = 0.0234
Distribution volume (L/kg) 0.77 (0.7–0.87) 0.59 (0.35–0.85) n.s.
Elimination half-life (h) 1.9 (1.8–2.5) 2.3 (1.4–3.6) n.s.
Table 2: Clinical characteristics and pharmacokinetic estimates for intravenous ketorolac (single dose, 30mg) in 8 women as collected at
delivery and in postpartum (17–23 weeks after delivery). Data provided by median and range.
At delivery Postpartum P value
Body weight (kg) 75.5 (60–85) 60.8 (48.8–87.2) P = 0.0156
Body surface area, BSA (m2) 1.89 (1.65–1.98) 1.69 (1.48–2.01) P = 0.0156
Clearance (L/h) 3.8 (2.68–4.50) 2.53 (1.4–3.02) P = 0.0078
Clearance (L/h·kg) 0.05 (0.03–0.07) 0.04 (0.02–0.06) P = 0.0469
Clearance/BSA (L/h·m2) 2.03 (1.35–2.66) 1.43 (0.88–1.83) P = 0.0391
Distribution volume (L) 14.6 (10.8–27.7) 10.88 (6.94–14.01) P = 0.0156
Distribution volume (L/kg) 0.19 (0.15–0.38) 0.16 (0.11–0.24) P = 0.0391
Elimination half-life (h) 3.08 (1.85–4.79) 2.84 (2.28–5.11) n.s.
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Figure 1: Paired intraindividual estimates for intravenous parac-
etamol clearance at delivery or in postpartum (L/h·m2) and mean
with standard deviation for both time intervals.
4. Discussion
Knowledge on population-speciﬁc dose exposure to predict
population-speciﬁc dose response relationship remains a
clinical challenge [1–4]. In the current paper, we quantiﬁed
the impact of post-caesarean delivery compared to postpar-
tum for both iv paracetamol and ketorolac PK, using an
intraindividual approach.
We recently reported on the impact of pregnancy on
iv paracetamol loading dose PK and compared—using an
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Figure 2: Paired individual estimates for intravenous ketorolac
clearance at delivery or in postpartum (L/h·m2) and mean with
standard deviation for both time intervals.
unpaired approach—observations at delivery in 28 women
(median clearance 10.9L/h·m2) with similar observations
(single iv loading dose, 2g paracetamol) in 14 healthy female
volunteers (median clearance 9.6L/h·m2) as published by
Gregoire et al. [6, 9]. Using a paired approach in 8 women at
delivery and in postpartum in the current paper, we conﬁrm
the higher paracetamol clearance at delivery when compared
to 10–15 weeks postpartum (11.7 to 6.4L/h·m2). The same
conclusions can be drawn for the ketorolac observations:
when compared with data as published in the literature4 Journal of Biomedicine and Biotechnology
in 13 healthy male volunteers (1.48L/h·m2, single-dose iv
ketorolac tromethamine 30mg), median ketorolac clearance
was higher at delivery with a subsequent decrease (2.03 to
1.43L/h·m2)i np o s t p a r t u m[ 10].
In healthy adults, paracetamol is almost exclusively elim-
inated by conjugation into either paracetamol glucuronide
(47–62%) or paracetamol sulphate (25–36%), while limited
amounts (1–4%) are excreted in the urine as unchanged
paracetamol or undergo (<10%) oxidation to result in
toxic metabolites (N-acetyl-p-benzoquinone, NAPQI) [9,
11]. Paracetamol glucuronidation occurs mainly through
uridine 5 -diphosphate glucuronosyltransferase (UGT) 1A6
and to a much lesser extent by UGT-1A1 and UGT-1A9,
oxidation by cytochrome P450 (CYP) CYP2E1 and CYP2A1
[11]. Following oral paracetamol administration in pregnant
women,paracetamolclearancewas58%higher,secondaryto
a 75% increase in glucuronidation activity of UGT1A6 and
UGT1A1 with unaltered sulphation activity [12].
Similarly, ketorolac also mainly undergoes glucuronida-
tion (72–77%, likely UGT2B7) with limited cytochrome
P450 (CYP) 2C-related (para-hydroxy-ketorolac) metabolic
clearance. We are unaware of any data of ketorolac
metabolism during pregnancy [13, 14]. Based on in vivo
alterations in oxazepam clearance, it is generally believed
that the in vivo UGT2B7 activity is also increased during
pregnancy [1]. For both compounds evaluated, changes in
oxidation (CYP2E1, CYP2A1, CYP2C) or in protein binding
(ketorolac is highly albumin bound) may further contribute
to the phenotypic increase in clearance observed at caesarean
delivery in addition to the increase in glucuronidation.
Besides pregnancy itself, the disposition of analgesics
in our study may be further aﬀected by procedure-related
issues like the extent of the surgical trauma, ﬂuid shifts, or
comedication. In a dental pain model, Jamali and Kunz-
Dober documented that ibuprofen disposition was aﬀected
by the presence of surgical stress [15]. Although these
authors mainly related these diﬀerences to altered gastric
emptying and absorption, we would like to stress that also
our observations are phenotypic estimates and may have
beenmodulatedbyothercovariates,includingsurgicalstress,
in addition to the pregnant status.
The subsequent extrapolation of population-speciﬁc PK
to eﬀective post-caesarean analgesia (PD) is not a simple
extrapolation of these PK diﬀerences. However, the pheno-
typic PK estimates serve to develop population-tailored dos-
ing guidelines, that subsequently need prospective validation
and are a ﬁrst, but essential step towards improved analgesia
[5, 10, 11, 13]. We hereby have to take into account that
PD may also be altered due to pregnancy or delivery. When
applied to analgesia after caesarean delivery, not only labour
prior to the caesarean delivery and patient characteristics
(individual thermal pain thresholds, personality characteris-
tics) but also duration of surgery aﬀect pain reporting and
analgesic needs after caesarean delivery [6].
Our observations also provide some preliminary in vivo
observations on the alterations in PK in postpartum [1].
Paracetamol clearance 10–15 weeks after delivery decreased
to 6.4L/h·m2. This is signiﬁcantly lower (9.6L/h·m2) when
compared to observations in healthy female volunteers of
Gregoire et al. [9]. Median ketorolac clearance 17–23 weeks
after delivery decreased to 1.43L/h·m2, similar to median
ketorolac clearance reported in 13 healthy male volun-
teers (1.48L/h·m2)[ 10]. Although limited to paracetamol
because of absence of ketorolac PK in healthy nonpregnant
female volunteers, the paracetamol observations suggest
that women during the postpartum period should also be
considered as another speciﬁc subpopulation: it seems that
paracetamol clearance in postpartum initially decreases to
values even lower than healthy female volunteers. Explo-
ration of the links between the physiological changes and
the pharmacokinetic in vivo changes should guide further
research, similar to the methodology of physiologicallybased
pharmacokinetic modeling for other special populations like
pediatrics [3, 16, 17].
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